Levosimendan improves event free survival by 50 percent in end-stage heart failure

Ambulatory levosimendan improves event free survival by 50 percent compared to placebo, according to results from the LevoRep Study presented today during the late breaking trial session1 of the Heart Failure Congress 2013. In a second study, the third generation mineralocorticoid receptor antagonist BAY 94-8862 showed improved potassium and kidney tolerance in heart failure patients with chronic kidney disease.

Fuente : http://www.eurekalert.org/pub_releases/2013-05/eso…